Literature DB >> 6326661

Acyclovir and other chemotherapy for herpes group viral infections.

H H Balfour.   

Abstract

The recent profusion of antiviral research has resulted in significant advances toward prevention and treatment of herpes group virus infections. The most promising new agent is acyclovir, which is available in topical, intravenous, and oral formulations. Results of clinical trials of acyclovir for prevention and treatment of herpes simplex, varicella-zoster virus, cytomegalovirus, and Epstein-Barr virus infections are discussed, and the potential problem of antiviral resistance considered. Vidarabine therapy is reviewed briefly, and future new drugs with activity against herpesviruses are mentioned.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6326661     DOI： 10.1146/annurev.me.35.020184.001431

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN： 0066-4219            Impact factor:   13.739


  5 in total

1.  Topical Acyclovir for Recurrent Herpes Labialis in Primary Care: Critical appraisal.

Authors:  G Worrall
Journal:  Can Fam Physician       Date:  1991-01       Impact factor: 3.275

2.  Clinical characteristics of acyclovir-resistant herpetic keratitis and experimental studies of isolates.

Authors:  Y F Yao; Y Inoue; T Kase; Y Uchihori; Y Mori; Y Ohashi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-08       Impact factor: 3.117

3.  9-(2'-Deoxy-2'-Fluoro-β-d-Arabinofuranosyl) Adenine Is a Potent Antitrypanosomal Adenosine Analogue That Circumvents Transport-Related Drug Resistance.

Authors:  Farahnaz Ranjbarian; Munender Vodnala; Khalid J H Alzahrani; Godwin U Ebiloma; Harry P de Koning; Anders Hofer
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

4.  Role of genotypic analysis of the thymidine kinase gene of herpes simplex virus for determination of neurovirulence and resistance to acyclovir.

Authors:  N Y Lee; Y Tang; M J Espy; C P Kolbert; P N Rys; P S Mitchell; S P Day; S L Henry; D H Persing; T F Smith
Journal:  J Clin Microbiol       Date:  1999-10       Impact factor: 5.948

5.  The small molecules AZD0530 and dasatinib inhibit dengue virus RNA replication via Fyn kinase.

Authors:  Melissanne de Wispelaere; Amy J LaCroix; Priscilla L Yang
Journal:  J Virol       Date:  2013-04-24       Impact factor: 5.103
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.